J Gynecol Oncol.
2016 May;27(3):e30. 10.3802/jgo.2016.27.e30.
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline
- Min KJ
- Kwon SH
- Kim S
- Kim HJ
- Seong SJ
- Song YJ
- Shin JW
- Lee KH
- Lim MC
- Chung HH
- Ju W
- Hong JH
- Lee JW
- Kim JW
- Bae DS
- Lee JK
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea. jklee38@gmail.com
- 2Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
- 3Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
- 4Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.
- 5Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, Seoul, Korea.
- 6Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Yangsan, Korea.
- 7Department of Obstetrics and Gynecology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
- 8Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 9Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
- 10Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- 11Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea.
- 12Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- KMID: 2363324
- DOI: http://doi.org/10.3802/jgo.2016.27.e30
Abstract
- After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and reviewed the literatures focused on the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the ability of cross-protection of each HPV preventive vaccine. The KSGO has revised the previous guideline based on the results of the above studies.
MeSH Terms
-
Adolescent
Adult
Age Factors
Child
Female
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18/administration & dosage/adverse effects/therapeutic u
Humans
Middle Aged
Papillomavirus Vaccines/administration & dosage/adverse effects/*therapeutic use
*Practice Guidelines as Topic
Republic of Korea
Treatment Outcome
Uterine Cervical Neoplasms/*prevention & control
Young Adult
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Papillomavirus Vaccines
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV
- Current status of cervical cancer and HPV infection in Korea
- Who should be offered non-radical surgery for early-stage cervical cancer?
- Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
- Unexpected result of minimally invasive surgery for cervical cancer
